Overview

Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

Status:
Completed
Trial end date:
2017-09-26
Target enrollment:
Participant gender:
Summary
to evaluate the effect of the PPI (rabeprazole) on the PK of a potential commercial tablet formulation of palbociclib
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Palbociclib
Proton Pump Inhibitors
Rabeprazole